Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Research and Development (R&D) Expense Ratio for the quarter ending March 31, 2024

Biomea Fusion Inc Research and Development (R&D) Expense Ratio is NA for the quarter ending March 31, 2024. The RD expense ratio measures the proportion of a company's research and development (R&D) expenses to its revenue. It is calculated by dividing the R&D expenses by the revenue. This ratio indicates the level of investment in R&D relative to the company's revenue generation. A higher ratio suggests a greater allocation of resources towards research and development activities, indicating a focus on innovation and potential future growth.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email